Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP368796.RAhXMnACR9CTY04KppGsNU3Xj6lHqylQ5dP1EB0-i30WE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP368796.RAhXMnACR9CTY04KppGsNU3Xj6lHqylQ5dP1EB0-i30WE130_assertion type Assertion NP368796.RAhXMnACR9CTY04KppGsNU3Xj6lHqylQ5dP1EB0-i30WE130_head.
- NP368796.RAhXMnACR9CTY04KppGsNU3Xj6lHqylQ5dP1EB0-i30WE130_assertion description "[The use of monoclonal antibodies in colorectal and gastric cancers showed the best outcomes when combined with chemotherapy, even though single agent anti-EGFR antibodies seem active in particular setting of metastatic colorectal cancer (CRC) patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP368796.RAhXMnACR9CTY04KppGsNU3Xj6lHqylQ5dP1EB0-i30WE130_provenance.
- NP368796.RAhXMnACR9CTY04KppGsNU3Xj6lHqylQ5dP1EB0-i30WE130_assertion evidence source_evidence_literature NP368796.RAhXMnACR9CTY04KppGsNU3Xj6lHqylQ5dP1EB0-i30WE130_provenance.
- NP368796.RAhXMnACR9CTY04KppGsNU3Xj6lHqylQ5dP1EB0-i30WE130_assertion SIO_000772 23441760 NP368796.RAhXMnACR9CTY04KppGsNU3Xj6lHqylQ5dP1EB0-i30WE130_provenance.
- NP368796.RAhXMnACR9CTY04KppGsNU3Xj6lHqylQ5dP1EB0-i30WE130_assertion wasDerivedFrom befree-20150227 NP368796.RAhXMnACR9CTY04KppGsNU3Xj6lHqylQ5dP1EB0-i30WE130_provenance.
- NP368796.RAhXMnACR9CTY04KppGsNU3Xj6lHqylQ5dP1EB0-i30WE130_assertion wasGeneratedBy ECO_0000203 NP368796.RAhXMnACR9CTY04KppGsNU3Xj6lHqylQ5dP1EB0-i30WE130_provenance.